Biotest Aktiengesellschaft (BIO3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biotest Aktiengesellschaft (BIO3) has a cash flow conversion efficiency ratio of -0.114x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-58.10 Million ≈ $-67.93 Million USD) by net assets (€509.60 Million ≈ $595.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Biotest Aktiengesellschaft (BIO3) total market value for the company's overall valuation and market capitalisation.
Biotest Aktiengesellschaft - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Biotest Aktiengesellschaft's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biotest Aktiengesellschaft Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotest Aktiengesellschaft ranked by their cash flow conversion efficiency. Explore Biotest Aktiengesellschaft (BIO3) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Liberty Broadband Srs A
NASDAQ:LBRDA
|
-0.012x |
|
Ballard Power Systems Inc
TO:BLDP
|
-0.038x |
|
Hunan Airbluer Environmental Protection Technology Co. Ltd.
SHE:301259
|
N/A |
|
King-Strong New Material Technology Co Ltd
SHE:300629
|
-0.006x |
|
Shanghai Kelai Mechatronics
SHG:603960
|
0.027x |
|
Chapters Group AG
XETRA:CHG
|
0.040x |
|
ACNB Corporation
NASDAQ:ACNB
|
-0.008x |
|
Mengtian Home Group Inc.
SHG:603216
|
N/A |
Annual Cash Flow Conversion Efficiency for Biotest Aktiengesellschaft (2002–2024)
The table below shows the annual cash flow conversion efficiency of Biotest Aktiengesellschaft from 2002 to 2024. View Biotest Aktiengesellschaft share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €530.70 Million ≈ $620.44 Million |
€60.90 Million ≈ $71.20 Million |
0.115x | +2220.40% |
| 2023-12-31 | €498.90 Million ≈ $583.27 Million |
€-2.70 Million ≈ $-3.16 Million |
-0.005x | +95.04% |
| 2022-12-31 | €371.10 Million ≈ $433.85 Million |
€-40.50 Million ≈ $-47.35 Million |
-0.109x | -222.46% |
| 2021-12-31 | €380.40 Million ≈ $444.73 Million |
€33.90 Million ≈ $39.63 Million |
0.089x | +335.65% |
| 2020-12-31 | €441.60 Million ≈ $516.28 Million |
€-16.70 Million ≈ $-19.52 Million |
-0.038x | +46.32% |
| 2019-12-31 | €476.90 Million ≈ $557.55 Million |
€-33.60 Million ≈ $-39.28 Million |
-0.070x | +30.22% |
| 2018-12-31 | €495.20 Million ≈ $578.94 Million |
€-50.00 Million ≈ $-58.46 Million |
-0.101x | -202.38% |
| 2017-12-31 | €347.80 Million ≈ $406.61 Million |
€34.30 Million ≈ $40.10 Million |
0.099x | -46.02% |
| 2016-12-31 | €360.70 Million ≈ $421.70 Million |
€65.90 Million ≈ $77.04 Million |
0.183x | +97.71% |
| 2015-12-31 | €412.30 Million ≈ $482.02 Million |
€38.10 Million ≈ $44.54 Million |
0.092x | +489.25% |
| 2014-12-31 | €480.20 Million ≈ $561.40 Million |
€-11.40 Million ≈ $-13.33 Million |
-0.024x | -51.90% |
| 2013-12-31 | €460.70 Million ≈ $538.61 Million |
€-7.20 Million ≈ $-8.42 Million |
-0.016x | -116.63% |
| 2012-12-31 | €369.43 Million ≈ $431.91 Million |
€34.73 Million ≈ $40.60 Million |
0.094x | -54.92% |
| 2011-12-31 | €346.67 Million ≈ $405.29 Million |
€72.28 Million ≈ $84.50 Million |
0.208x | -17.59% |
| 2010-12-31 | €307.61 Million ≈ $359.63 Million |
€77.83 Million ≈ $90.99 Million |
0.253x | +115.51% |
| 2009-12-31 | €269.86 Million ≈ $315.50 Million |
€31.68 Million ≈ $37.04 Million |
0.117x | -13.75% |
| 2008-12-31 | €253.37 Million ≈ $296.22 Million |
€34.49 Million ≈ $40.32 Million |
0.136x | -5.47% |
| 2007-12-31 | €225.76 Million ≈ $263.94 Million |
€32.51 Million ≈ $38.01 Million |
0.144x | -1.85% |
| 2006-12-31 | €179.31 Million ≈ $209.64 Million |
€26.31 Million ≈ $30.76 Million |
0.147x | -12.46% |
| 2005-12-31 | €168.97 Million ≈ $197.55 Million |
€28.32 Million ≈ $33.11 Million |
0.168x | -28.46% |
| 2004-12-31 | €107.97 Million ≈ $126.22 Million |
€25.29 Million ≈ $29.57 Million |
0.234x | +46.49% |
| 2003-12-31 | €103.29 Million ≈ $120.75 Million |
€16.52 Million ≈ $19.31 Million |
0.160x | +619.93% |
| 2002-12-31 | €110.79 Million ≈ $129.53 Million |
€2.46 Million ≈ $2.88 Million |
0.022x | -- |
About Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for… Read more